Kyle Lefkoff is Executive Chairman and Founder of Ambrosia Biosciences and Founder and General Partner of Boulder Ventures Ltd., with nearly four decades of experience investing in and building life sciences companies. Over his career, he has invested in more than 60 Colorado-based companies, including numerous successful life sciences exits and public companies. He is a founder and former Chairman of Array BioPharma, which was acquired by Pfizer for $11.8 billion, and served as Chairman of ArcherDX through its $2.7 billion acquisition by Invitae. Kyle holds a BA in Economics from Vassar College and an MBA in Finance from the University of Chicago, and brings deep board-level and venture leadership to Ambrosia.

Nick Traggis is a serial entrepreneur with a track record of building and scaling companies across biotech, diagnostics, and other physical sciences. Most recently, he served as CEO of Lightdeck Diagnostics, where he led development of a point-of-care diagnostics platform and negotiated the company’s successful acquisition by Heska in 2023. Prior to that, he worked as the General Manager of Precision Photonics;  ultimately selling to IDEX Corporation, where he remained as the Chief Technology Officer. Nick has led or advised on seven M&A transactions, over 20 technology licensing agreements, and raised over $130 million in financing. He holds a BS in Metallurgical and Materials Engineering from the Colorado School of Mines.

David Snitman was a Co-Founder of Array BioPharma, where he served as Chief Operating Officer and Vice President of Business Development from 1998 to 2015 and helped shape the company’s long-term strategy. He played a central role in building Array into a leading biopharmaceutical company, securing strategic partnerships and advancing multiple drug discovery programs. Prior to Array, Dr. Snitman held senior roles at Amgen, including Associate Director of New Products and Technology and Manager of the Boulder research facility. He holds a PhD in Chemistry from the University of Colorado, completed postdoctoral training at MIT as an NIH Fellow, and brings deep business development expertise to Ambrosia Biosciences.

William Marshall is a seasoned life sciences executive with more than three decades of experience in RNA therapeutics, drug discovery, and biotech leadership. He currently serves as Chief Executive Officer of Ribometrix Inc., where he is advancing a leading RNA-targeting small-molecule platform and a growing preclinical pipeline. Previously, William was CEO and Co-Founder of miRagen Therapeutics (NASDAQ: MGEN), which merged with Viridian Therapeutics, and held senior leadership roles at Dharmacon, Thermo Fisher Scientific, and Amgen. He holds a PhD in Chemistry from the University of Colorado Boulder, has authored over 50 scientific publications and 70 patents, and serves on the boards of multiple biotechnology companies.

John Orwin is a Venture Partner at Samsara BioCapital. Previously, he served as CEO of Relypsa, where he led the launch of Veltassa® (patiromer) and the company’s acquisition by Galenica for more than $1.5 billion. His career also includes CEO of Altreca, CEO of Affymax, Senior Vice President of BioOncology at Genentech, and senior leadership roles at Johnson & Johnson, Alza Pharmaceuticals, Sangstat Medical, Rhone-Poulenc Rorer, and Schering-Plough. John currently chairs the boards of AnaptysBio and Nested Therapeutics, serves on the boards of CARGO Therapeutics (as chair), Seagen, and Array BioPharma.

Jason Haddock is a seasoned biopharmaceutical finance and operations executive with more than 25 years of industry experience. He previously served as Chief Financial Officer of Array BioPharma, where he helped execute an oncology-focused R&D and commercialization strategy that led to the successful launch of two drugs and the company’s acquisition by Pfizer. Earlier in his career, Jason held senior finance, strategic, and operational leadership roles at Bristol Myers Squibb across Asia Pacific, Europe, and the United States, including CFO and COO positions. He currently serves on the boards of PYC Therapeutics and Merus N.V. and holds a bachelor’s degree in accountancy and an EMBA from Washington University in St. Louis.

John Mayer brings decades of experience in peptide chemistry and metabolic disease drug development. He began his career at Amgen and later led peptide chemistry groups at Eli Lilly and Novo Nordisk, where he contributed to the development of GLP-1 and related therapeutics. In 2017, John joined the faculty of Molecular, Cellular & Developmental Biology at the University of Colorado Boulder and continues to contribute to academic and industry drug discovery efforts. His scientific leadership and strategic guidance are central to advancing Ambrosia’s research and development programs in obesity and metabolic disease.

Richard DiMarchi is a Distinguished Professor of Chemistry and the Linda & Jack Gill Chair in Biomolecular Sciences at Indiana University, and a globally recognized leader in metabolic disease therapeutics. He is renowned for pioneering work in GLP-1 and incretin-based therapies and has contributed to the discovery and development of Humalog®, rGlucagon®, and Forteo®. Richard is a member of the National Academy of Medicine and the National Inventors Hall of Fame, and has co-founded multiple successful biotechnology companies, including Marcadia and Calibrium. He has authored more than 250 scientific publications, holds over 100 U.S. patents, and continues to shape the field of diabetes and obesity drug development through both academic and commercial innovation.

Tom Hughes is a veteran metabolic disease and drug development executive with more than 35 years of experience advancing therapies for diabetes and obesity. He has served as Chief Executive Officer of Navitor Pharmaceuticals since 2018 and currently serves on the boards of Totus Medicines and Eikonizo Therapeutics, and is an advisor of several biotechnology companies and venture capital firms. Previously, Tom was President, Chief Scientific Officer, and CEO of Zafgen, where he led the advancement of beloranib through clinical development. Earlier in his career, he held senior leadership roles at Novartis, including Global Head of Cardiovascular and Metabolic Diseases at the Novartis Institutes for BioMedical Research.

Kieran Chacko is Executive Vice President of Data Science and Corporate Strategy at Harbinger Health and a co-founder and Advisory Board member of Ambrosia Biosciences. He brings deep experience in biotechnology venture creation, company building, and corporate strategy. As a founding member of Harbinger Health, he has helped lead corporate strategy and raise approximately $200 million in private financing, and previously served as a Principal at Flagship Pioneering, where he helped create and build multiple oncology-focused platform companies. Kieran began his career in investment banking at J.P. Morgan and holds a doctorate in Computational Biology from the Icahn School of Medicine at Mount Sinai.

Nick Saccomano is President and Chief Executive Officer of OnKure, Inc., and a biopharmaceutical executive with nearly 35 years of experience leading pharmaceutical research and development. Previously, he served as Chief Science Officer and Site Head at Pfizer’s Boulder facility, overseeing a 170-scientist organization advancing small-molecule drug programs. Earlier in his career, Nick was Chief Science Officer at Array BioPharma, where he helped create and advance ten clinical-stage compounds, seven of which have achieved drug approval, and served as Chief Technology Officer at SomaLogic. He holds a PhD in Organic Chemistry from Columbia University and continues to advise multiple innovative biotechnology companies.